Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Moderna Inc

Healthcare US MRNA

54.98USD
-0.76(1.36%)

Last update at 2026-03-10T20:28:00Z

Day Range

52.6556.16
LowHigh

52 Week Range

62.55170.47
LowHigh

Fundamentals

  • Previous Close 55.74
  • Market Cap58712.37M
  • Volume7258002
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4560.00000M
  • Revenue TTM5153.00M
  • Revenue Per Share TTM13.53
  • Gross Profit TTM 10552.00M
  • Diluted EPS TTM-15.59

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 9575.00M 13285.00M -744.51300M -514.71600M -384.40800M
Minority interest - - - - -
Net income 8362.00M 12202.00M -747.06400M -514.02100M -384.73400M
Selling general administrative 1132.00M 567.00M 188.27M 109.62M 94.25M
Selling and marketing expenses - - - - -
Gross profit 13847.00M 15119.00M 266.56M 48.04M 135.07M
Reconciled depreciation 348.00M 232.00M 31.25M 31.02M 24.86M
Ebit 9420.00M 13064.00M -794.39500M -576.74100M -438.12800M
Ebitda 9768.00M 13296.00M -763.14400M -545.72000M -413.26600M
Depreciation and amortization 348.00M 232.00M 31.25M 31.02M 24.86M
Non operating income net other 155.00M -11.00000M 18.63M 31.00M 28.86M
Operating income 9420.00M 13296.00M -763.14400M -545.72000M -413.26600M
Other operating expenses 9843.00M 4440.00M 1037.63M 593.76M 535.78M
Interest expense 29.00M 18.00M 9.89M 6.61M 0.00000M
Tax provision 1213.00M 1083.00M 2.55M -0.69500M 0.33M
Interest income 200.00M 18.00M 24.71M 38.53M 27.02M
Net interest income 200.00M 18.00M 14.83M 31.92M 27.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1213.00M 1083.00M 2.55M -0.69500M 0.33M
Total revenue 19263.00M 17736.00M 274.49M 48.04M 122.51M
Total operating expenses 4427.00M 1823.00M 1029.70M 593.76M 535.78M
Cost of revenue 5416.00M 2617.00M 7.93M 496.31M -12.55600M
Total other income expense net 155.00M -11.00000M 18.63M 31.00M 1.83M
Discontinued operations - - - - -
Net income from continuing ops 8362.00M 12202.00M -747.06400M -514.02100M -384.73400M
Net income applicable to common shares 8362.00M 12202.00M -747.06400M -514.02100M -401.85700M
Preferred stock and other adjustments - - - - 17.12M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 18426.00M 25858.00M 24669.00M 7336.75M 1589.42M
Intangible assets 44.00M - - - -
Earning assets - - - - -
Other current assets 88.00M 1195.00M 55.00M -405.63100M 887.90M
Total liab 4572.00M 6735.00M 10524.00M 4775.38M 414.61M
Total stockholder equity 13854.00M 19123.00M 14145.00M 2561.38M 1174.81M
Deferred long term liab - - - - -
Other current liab 1902.00M 2202.00M 2362.00M 33.66M 5.06M
Common stock - - -857.00000M 0.04M 0.03M
Capital stock 0.00000M 0.00000M 0.00000M 0.04M 0.03M
Retained earnings 13606.00M 18320.00M 9958.00M -2243.51800M -1496.45400M
Other liab - 808.00M 691.00M 179.27M 139.13M
Good will 52.00M - - - -
Other assets - 1928.00M 7383.00M 741.98M 12.72M
Cash 2907.00M 3205.00M 6848.00M 2623.85M 235.88M
Cash and equivalents - - - - -
Total current liabilities 3015.00M 4923.00M 9128.00M 4388.81M 143.12M
Current deferred revenue 568.00M 2038.00M 6253.00M 3867.19M 63.31M
Net debt -1664.00000M -2005.00000M -5932.00000M -2416.55500M -103.51200M
Short term debt 25.00M 196.00M 211.00M 469.59M 67.65M
Short long term debt - - - - -
Short long term debt total 1243.00M 1200.00M 916.00M 207.29M 132.36M
Other stockholder equity 371.00M 1173.00M 4211.00M 4801.85M 2669.43M
Property plant equipment - 2139.00M 1383.00M 387.09M 287.91M
Total current assets 10325.00M 13431.00M 17570.00M 6297.88M 1262.99M
Long term investments 4743.00M 8318.00M 6843.00M 638.85M 159.99M
Net tangible assets - 19123.00M 14145.00M 2561.38M 1174.81M
Short term investments 5697.00M 6697.00M 3879.00M 1983.76M 867.12M
Net receivables 1081.00M 1385.00M 3296.00M 1410.53M 16.30M
Long term debt - - - - -
Inventory 202.00M 949.00M 1441.00M 46.53M -904.19300M
Accounts payable 520.00M 487.00M 302.00M 18.36M 7.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -123.00000M -370.00000M -24.00000M 3.00M 1.80M
Additional paid in capital - - - - -
Common stock total equity - - - 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - 18320.00M 9958.00M -2243.51800M -1500.00000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 523.00M 988.00M 46.00M 12.93M -121.46100M
Deferred long term asset charges - - - - -
Non current assets total 8101.00M 12427.00M 7099.00M 1038.87M 326.44M
Capital lease obligations 1243.00M 1004.00M 916.00M 207.29M 132.36M
Long term debt total - - - - 38.69M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -5176.00000M -8239.00000M -1604.48000M 16.61M -267.32800M
Change to liabilities 112.00M 2192.00M 406.26M -77.61400M -40.54600M
Total cashflows from investing activities -5176.00000M -8523.00000M -1671.92800M -14.94500M -372.47200M
Net borrowings -184.00000M -140.00000M -6.21500M 0.97M 9.46M
Total cash from financing activities -3448.00000M -873.00000M 2033.19M 51.12M 1226.84M
Change to operating activities -992.00000M 582.00M 154.59M 7.20M 6.83M
Net income 8362.00M 12202.00M -747.06400M -514.02100M -384.73400M
Change in cash -3643.00000M 4224.00M 2388.24M -422.79200M 523.50M
Begin period cash flow 6860.00M 2636.00M 247.70M 670.49M 134.86M
End period cash flow 3217.00M 6860.00M 2635.93M 247.70M 658.36M
Total cash from operating activities 4981.00M 13620.00M 2026.97M -458.96800M -330.86500M
Issuance of capital stock 0.00000M 0.00000M 1852.72M 0.00000M 1224.14M
Depreciation 348.00M 232.00M 31.25M 31.02M 24.86M
Other cashflows from investing activities -40.00000M -30.00000M -30.00000M 16.61M 0.62M
Dividends paid - -124.00000M -7.04000M - -
Change to inventory 492.00M -1394.00000M -46.52700M 7.20M 4.41M
Change to account receivables 1790.00M -1784.00000M -1385.19100M 7.22M 0.83M
Sale purchase of stock -3329.00000M -857.00000M 7.04M 2.89M -8.18200M
Other cashflows from financing activities -184.00000M 124.00M 186.68M 0.97M 674.17M
Change to netincome -305.00000M -176.00000M 155.54M 81.44M 73.46M
Capital expenditures 400.00M 284.00M 67.45M 31.55M 105.77M
Change receivables 1790.00M -1784.00000M -1385.19100M 7.22M 0.83M
Cash flows other operating -5849.00000M 2294.00M 3602.52M 16.73M -2.86900M
Exchange rate changes - - - - -
Cash and cash equivalents changes -3643.00000M 4224.00M 2388.24M -422.79200M 523.50M
Change in working capital -3455.00000M 990.00M 2577.05M -53.66400M -42.58300M
Stock based compensation 226.00M 142.00M 93.02M 81.12M 72.56M
Other non cash items 59.00M 372.00M 62.29M -3.42600M -0.97500M
Free cash flow 4581.00M 13336.00M 1959.52M -490.52200M -436.63100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MRNA
Moderna Inc		 -0.76 1.36% 54.98 - 32.47 5.88 2.91 4.87 -10.0256
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna Inc

200 Technology Square, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. Noubar B. Afeyan Ph.D. Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board 1963
Mr. Stephane Bancel CEO & Director 1973
Dr. Stephen Hoge M.D. Pres 1976
Ms. Shannon Thyme Klinger Chief Legal Officer & Corp. Sec. 1971
Mr. Juan Andres Pres of Strategic Partnerships & Enterprise Expansion 1965
Mr. James M. Mock Chief Financial Officer 1977
Dr. Jerh Collins Ph.D. Chief Technical Operations & Quality Officer NA
Dr. John V. W. Reynders Ph.D. Chief Information Officer NA
Dr. Melissa J. Moore Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board NA
Ms. Lavina Talukdar CFA Sr. VP & Head of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.